Alembic Pharmaceuticals Limited · NSE:APLLTD
Alembic Pharmaceuticals — Q1 FY2016 Earnings Presentation
28 slides from Alembic Pharmaceuticals's earnings presentation, July 2015
Slide 1: Investor Presentation
Alembic Pharmaceuticals Limited Investor Presentation July 2015 BSE Code: 533573 NSE Code: APLLTD Bloomberg Code: ALPM:IN Reuters Code: ALEM.NS www.alembic-india.com
Slide 2: Safe Harbor Statement
Safe Harbor Statement Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to diffe
Slide 3: The Journey so far
The Journey so far 1971 1940 1907 Becomes 1st Indian company to Starts manufacturing cough syrup, Alembic Ltd. starts manufacturing manufacture Erythromycin vitamins, tonics and sculpture drugs tinctures and alcohol at Vadodara 1972 1961 Launched it under brand Penicillin plant inaugurated ‘ALTHROCI
Slide 4: Revenue Overview Q1FY16
Revenue Overview Q1FY16 % of the total sales 5 21 India Branded Formulations 18 International Generics 45 API Export India Generics API Domestic 29 International Branded Formulations
Slide 5: R&D Infrastructure
R&D Infrastructure State-of-the-art Analytical & IPR infrastructure R&D facility F&D Capabilities Bio Equivalence Centre R&D centre has been Commissioned new F&D State-of-the art 90- recognized by DSIR, center in Hyderabad with bedded Bio Centre Govt. of India 40 scientist 100 Pilot studies High-end
Slide 6: R&D spends to continue rising
R&D spends to continue rising 140 Total R&D spend 139 131 R&D spend as a % to sales 12 120 10.60 10 100 Rs. in Crores 77 8 80 70 % of sales 7.00 6.74 60 6 4.78 5.06 63 40 4 20 2 - 0 FY12 FY12 FY13 FY13 FY14 FY14 FY15 FY15 Q1 FY16 Q1 FY16 • Highly talented pool of 450 research scientists working to a
Slide 7: State of the Art Manufacturing Facilities
State of the Art Manufacturing Facilities Formulations Located at Panelav, Gujarat USFDA, MCC, MHRA, ANVISA & TPD approved – for Generic exports Capacity - 7 bn tablets / capsules p.a. Located at Baddi, Himachal Pradesh WHO GMP approved Manufactures branded formulations and caters to domestic market
Slide 8: Formulations business accounts for ~80% of revenues
Formulations business accounts for ~80% of revenues
Slide 9: Branded business continues to grow
Branded business continues to grow
Slide 10: Strong domestic market presence
Strong domestic market presence 1.77% market share (Ranked 19th) in Indian formulations market as per IMS MAT data 2 brands featured among Sustained dominance in top 100 and 5 among top anti-infective, analgesics, 300 brands in India as cough and cold segments per IMS MAT data Key Highlights Robust
Slide 11: Continued shift towards Specialty therapies
Continued shift towards Specialty therapies Therapy Dominance 100 90 % of Domestic Formulations 80 37 46 43 54 51 70 58 60 50 40 30 63 54 57 46 49 20 42 10 0 FY11 FY12 FY13 FY14 FY15 Q1FY16 Specialty Acute
Slide 12: Therapy-wise Performance Q1 FY16
Therapy-wise Performance Q1 FY16 JUN QTR 2015 JUN QTR 2014 Therapy Market Alembic Alembic Therapy Market Alembic Alembic Therapy Growth Share Growth Growth Growth Share Growth Growth (ORG) (ORG) (ORG) (PRIM) (ORG) (ORG) (ORG) (PRIM) Cardiology 14 1.97 47 35 12 1.53 22 34 Anti Diabetic 19 1.55 41 31
Slide 13: Marketing Divisions - Specialty
Marketing Divisions - Specialty Corazon Cardio-Diabetes Summit Specia Urology Ouron Alcare Gynecology Zenovi Elena Specialty Enteron Gastroenterology Gastron Dermatology Corium Orthopedics Osteofit Ophthalmology Eyecare High end Respiratory Respiratory
Slide 14: Marketing Divisions
Marketing Divisions Megacare Veterinary Anti-infective Acute and Cold & Pharma Cough Animal Healthcare Maxis Poultry
Slide 15: Key Therapies & Brands
Key Therapies & Brands Therapeutic Segment-wise Break-up (Q1FY16) • Launched 12 product SKUs in the domestic market in Q1FY16. % of total domestic formulation revenue Brand Name Therapeutic Area Ranking Azithral Anti-infective 33 Althrocin Anti-infective 66 Wikoryl Respiratory 161 Anti Infectives 21
Slide 16: Branded Export business in investment phase
Branded Export business in investment phase Products filed in key markets (South East Asia, CIS and East Africa) Focus on Rest of the Expected to be of critical World markets mass in 3 years Key Highlights
Slide 17: International Generics will be the growth driver
International Generics will be the growth driver
Slide 18: Fast emerging player in international generics
Fast emerging player in international generics All Facilities approved for supply to regulated markets such as the US, Europe, Australia and Brazil Partnership with leading Launching its own front- generic players in the end marketing in the US US, Europe, Canada, Australia Key Highlights 43 ANDAs/N
Slide 19: API business accounts for ~20% of revenues
API business accounts for ~20% of revenues
Slide 20: Focus on Regulated Markets
Focus on Regulated Markets 40% of capacity being used for captive consumption More than 90% Capacity Key of sales are to expansion is in regulated progress Highlights markets / customers 73 DMFs filed
Slide 21: Financial Snapshot
Aes Financial Snapshot
Slide 22: Focus on shareholder value creation
Focus on shareholder value creation CAGR 85,699 Revenue 16% 100,000 EBITDA 27% 80,000 53,738 In INR mn PAT 31% 60,000 40,000 19,793 Market Capitalization 108% 20,000 20,677 18,684 - 20,000 Market Capitalization 15,260 FY13 FY14 FY15 15,000 In INR mn 10,000 3,577 4,061 2,829 5,000 2,520 1,652 2,355 -
Slide 23: Financial Highlights
Financial Highlights Particulars (INR mn) Q1FY16 Q1FY15 %Growth FY 14-15 FY 13-14 %Growth Formulations Revenue India Branded 2627 2233 18% 9808 8506 15% Generics 286 252 13% 1227 1207 2% International Branded 84 227 -63% 635 736 -14% Generics 1677 1138 47% 5185 4684 11% API Revenue 1168 1063 10% 366
Slide 24: Latest Shareholding Pattern
Latest Shareholding Pattern % of Total Shareholding 14 Promoter & Promoter group 12 FI/FII/MF 74 Public Market capitalization INR 125 bn Total paid-up share capital 377.03mn Total number of shares O/S 188.52mn No. of shareholders 50 K Free float market capitalization INR 32 bn
Slide 25: Way forward
Aes Way forward
Slide 26: Strategy going forward
Strategy going forward • Continue to focus on complex products. Expect to launch 7-9 products every year for the next three years in the US markets • Commercial launch in USA through our own front end. • Filing ANDAs/MAs in other international markets such as Europe, Australia, Canada, Brazil and So
Slide 27: Conference call details
Conference call details Date : Monday, July 31, 2015 Time : 05.30 pm IST India - Primary Number +91 22 39381028 India - Secondary Number +91 22 67468328 USA 1 866 746 2133 UK 0 808 101 1573 Singapore Toll Free No. 800 101 2045 Hong Kong Toll Free No. 800 964 448
Slide 28: About Alembic Pharmaceuticals Limited
About Alembic Pharmaceuticals Limited Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharm
Alembic Pharmaceuticals — Q1 FY2016 Earnings Presentation on 6ix